ClinicalTrials.gg
CompletedNCT01200758Updated Nov 27, 2018Results posted

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

A Phase 3 interventional study of Rituximab SC and Rituximab IV in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 152 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-27.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
12th of 171
410 · median 38
Started
2011
with 5 others
Phase 3
29 of 178
none open now
Registered
118th of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 12th largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2011, is one of 29 in phase 3, and was the 118th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This two-stage, multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, efficacy and safety of rituximab SC versus rituximab IV in participants with previously untreated follicular non-Hodgkin's lymphoma. Participants will be randomized to receive 375 milligrams per meter square (mg/m\^2) rituximab as IV infusion or 1400 milligrams (mg) rituximab SC. In addition, participants will receive standard chemotherapy. Participants who achieved a complete or partial response (PR) after 8 treatment cycles, will receive maintenance treatment for a further maximum number of 12 cycles. Maintenance treatment cycles will be repeated every 8 weeks. This is a two-stage study. Stage 1 was designed to confirm the chosen rituximab SC dose resulting in comparable rituximab serum Ctrough levels compared with rituximab IV, when given as part of induction treatment every 3 weeks. Enrollment for Stage 2 started after the rituximab SC dose was established in Stage 1. Stage 2 aimed to further investigate the efficacy and safety of rituximab SC compared with rituximab IV. The anticipated time on study treatment is 96 weeks.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cluster of differentiation 20 (CD20)-positive, follicular Non-Hodgkin's lymphoma grade 1, 2, 3a. A tumor must have been performed within 6 months before study entry with material available for central review
  • No prior treatment
  • (ECOG) performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • Grade 3b follicular lymphoma
  • Transformation to high-grade lymphoma secondary to follicular lymphoma
  • Types of Non-Hodgkin's lymphoma other than follicular lymphoma
  • Presence or history of central nervous system (CNS) disease
  • Corticoid therapy during the last 4 weeks, except prednisone treatment less than (\<) 20 milligrams per day (mg per day)
  • Known active bacterial, viral, fungal, or mycobacterial, or any major episode of infections requiring hospitalization or treatment with IV antibiotics within 4 weeks of start of study medication, or oral antibiotics within 2 weeks prior to start of study medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
410 participants (actual)

Study arms

  • Active comparator
    Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)

    Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.

    Drug: Rituximab IV · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone/Prednisolone

  • Experimental
    Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)

    First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.

    Drug: Rituximab SC · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone/Prednisolone

Interventions

  • First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.

    Also known as: MabThera

  • Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.

    Also known as: MabThera

  • Eight cycles of cyclophosphamide (750 mg/m\^2 IV) administered every 3 weeks.

  • Eight cycles of doxorubicin (50 mg/m\^2 IV) administered every 3 weeks.

  • Eight cycles of doxorubicin (1.4 mg/m\^2 IV) administered every 3 weeks.

  • DrugPrednisone/Prednisolone

    Drug pages: Prednisone · Prednisolone

    Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m\^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.

06

What researchers measure

Primary outcomes

  1. Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab

    Time frame: Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours predose on Cy8) of induction treatment (1 Cy=3 weeks)

  2. Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)

    Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (\>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

Secondary outcomes

  1. Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

    Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

  2. Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

    Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

  3. Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

    Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

  4. Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

    Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

  5. Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

    Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)

  6. Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL

    Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)

  7. Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL

    Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

    Time frame: Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)

  8. Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death

    Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

    Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

  9. Stage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHL

    PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. PFS analysis was performed using Kaplan - Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

    Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

  10. Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL

    Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

    Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

  11. Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL

    Event-free survival was defined as the time from randomization to disease progression/relapse, death or initiation of new NHL therapy. If the specified event (progression/relapse, death or new anti-lymphoma treatment) did not occur, event-free survival was censored at the last tumor assessment date either during treatment or follow up. Event-free survival analysis was performed using Kaplan-Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

    Time frame: Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)

  12. Percentage of Participants Who Died

    Time frame: Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])

  13. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. Participants without event were censored at the time of last follow-up information for survival, ie, at the last time known to be alive.

    Time frame: Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])

  14. Stage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab

    AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Predose (within 2 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy 7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])

    Time frame: Stage I (Induction): Predose (within 2 hour [hr]) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)

  15. Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab

    Predose (within 2 hr) and 24 hrs postdose on Cy7 (D1,3,7,15), predose (0 hr) on Cy8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])

    Time frame: Stage I (Induction): Predose (within 2hr) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)

  16. Stage I and II (Pooled): Ctrough of Rituximab at Each Induction Treatment Cycle

    Stage I and II (Induction): Rituximab IV: Predose (within 2 hr) on D1 of Cy1-8 (1 Cy=3 weeks \& 4 weeks for Cy8); Rituximab SC: Predose (within 2 hr) on D1 of Cy1 \& Cy3-8 (1 Cy=3 weeks and 4 weeks for Cy8), predose (within 2 hr) on D0 of Cy2 (up to data cutoff of 31 Oct 2013 \[up to 32 months\])

    Time frame: Stage I and II (Pooled): Predose (within 2hr) up to data cutoff of 31 Oct 2013 [up to 32 months]) (See detailed timeframe in Outcome Measure description)

  17. Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle

    Stage I and II (maintenance): D29 of Cy8 (induction; 1 Cy=4 weeks), predose (within 2 hr) on D1 of Cy9 to 19 (maintenance Cy1 to 12 \[1 Cy=8 weeks\]; up to data cutoff of 11 Jan 2016 \[up to 6 years\])

    Time frame: Stage I and II (maintenance): Predose (within 2hr) up to data cutoff of 11 Jan 2016 [up to 6 years]) (See detailed timeframe in Outcome Measure description)

  18. Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration

    Time frame: 12 weeks, 24 weeks, and 36 weeks after the last rituximab administration (up to data cutoff of 11 Jan 2016 [up to 6 years])

  19. Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase

    Depletion is defined as a cluster of differentiation (CD) 19 value \<80 cells per cubic millimeter (cells/mm\^3).

    Time frame: Stage I and II (induction): for rituximab IV - D1 of Cy 1 to 8 (1 Cy=3 weeks); for rituximab SC - D1 of Cy 1 and Cy 3 to 8, D0 of Cy 2

  20. Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase

    Depletion is defined as a CD19 value \<80 cells/mm\^3.

    Time frame: Stage I and II (maintenance): D1 of Cy 9 to 20 (1 Cy=8 weeks) (up to data cutoff of 11 Jan 2016 [up to 6 years])

  21. Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs) to Rituximab

    Levels of HACA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])

    Time frame: Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)

  22. Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Human Antibodies (HAHAs) to Rituximab

    Levels of HAHA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])

    Time frame: Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)

  23. Stage I and II (Pooled): Percentage of Responses Showing Time Saved of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20

    All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (\<) 1 hr, at least 1 hr but \<2 hrs, at least 2 hrs but \<3 hrs, at least 3 hrs but \<4 hrs, \>/=4 hrs. Staff were asked not to consider the time needed for the first IV administration. Analysis was done in all participants to show a comparison on the time saved by staffs when administered via SC and IV.

    Time frame: After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)

  24. Percentage of Responses Who Showed Rituximab SC Formulation Convenient as Compared to Rituximab IV Formulation as Assessed by Physician/Nurse Opinion

    All investigator physicians and nurses involved in this study were asked to complete question i.e. "Which formulation of rituximab (SC or IV) do you think is more convenient?" based on their experience with the rituximab SC and IV formulations across all participants and presented as rituximab SC is much more convenient; rituximab SC is a little more convenient; both formulations are equally convenient; rituximab IV is a little more convenient; and rituximab IV is much more convenient.

    Time frame: After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)

07

Results

Posted Aug 5, 2015

Participant flow

Stage I
Participant flow — Stage I
MilestoneStage I: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)Stage II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)
Started646300
Completed464600
Not completed181700
Withdrew: Death0100
Withdrew: Physician decision1100
Withdrew: Lack of efficacy2100
Withdrew: Adverse event5500
Withdrew: Withdrawal by subject1200
Withdrew: Disease progression9700
Stage 2
Participant flow — Stage 2
MilestoneStage I: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)Stage II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)
Started00141142
Completed0010092
Not completed004150
Withdrew: Disease progression001621
Withdrew: Lack of efficacy0042
Withdrew: Physician decision0057
Withdrew: Adverse event0059
Withdrew: Withdrawal by subject0041
Withdrew: Lost to follow-up0031
Withdrew: Protocol violation0014
Withdrew: Death0035

Outcome measures

PrimaryStage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab
Time frame:
Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours predose on Cy8) of induction treatment (1 Cy=3 weeks)
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab
micrograms per milliliter (mcg/mL)Stage I: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab83.1 ± 36.7134.6 ± 43.2
Statistical analysis
  • Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) · Geometric mean ratio: 1.62 · 90% CI 1.36 to 1.94Geometric mean ratio adjusted for tumor load at baseline.
PrimaryStage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)

Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (\>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (≥) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Reported as:
Number · percentage of participants
Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)
percentage of participantsStage II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)85.1 (78.1 to 90.5)80.3 (72.8 to 86.5)
Statistical analysis
  • Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.2835 · Difference in response rates: -4.82 · 95% CI -14.0 to 4.4The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.
  • Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) · Odds ratio (or): 0.71 · 95% CI 0.38 to 1.33
SecondaryStage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Overall Response comprised CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in the SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Reported as:
Number · percentage of participants
Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage I: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL82.8 (71.3 to 91.1)90.5 (80.4 to 96.4)
Statistical analysis
  • Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.2047 · Difference in response rates: 7.66 · 95% CI -5.0 to 20.3The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.
  • Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) · Odds ratio (or): 1.97 · 95% CI 0.68 to 5.71
SecondaryStage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD; PR: ≥50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL84.9 (79.2 to 89.5)84.4 (78.7 to 89.1)
Statistical analysis
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.8911 · Difference in response rates: -0.49 · 95% CI -7.7 to 6.8The 95% CI for the difference in response rates was estimated using the Hauck-Anderson.
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) · Odds ratio (or): 0.96 · 95% CI 0.56 to 1.65
SecondaryStage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response was comprised CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage I: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Reported as:
Number · percentage of participants
Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage I: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL25.0 (15.0 to 37.4)42.9 (30.5 to 56.0)
Statistical analysis
  • Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.0335 · Difference in crr: 17.86 · 95% CI 0.8 to 35.0The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.
  • Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) · Odds ratio (or): 2.25 · 95% CI 1.06 to 4.78
SecondaryStage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Reported as:
Number · percentage of participants
Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL34.8 (26.9 to 43.2)28.2 (20.9 to 36.3)
Statistical analysis
  • Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.2331 · Difference in response rates: -6.58 · 95% CI -17.8 to 4.6The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.
  • Stage II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage II: Rituximab SC + Chemotherapy (CHOP/CVP) · Odds ratio (or): 0.74 · 95% CI 0.44 to 1.22
SecondaryStage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage I and II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for NHL31.7 (25.4 to 38.6)32.2 (25.9 to 39.1)
Statistical analysis
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.9157 · Difference in response rates: 0.49 · 95% CI -8.8 to 9.8The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) · Odds ratio (or): 1.00 · 95% CI 0.66 to 1.51
SecondaryStage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL

Complete Response comprised of CR and CRu. A participant was defined as a responder if they sustained a CR or CRu at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL57.9 (50.3 to 65.2)50.6 (42.9 to 58.3)
Statistical analysis
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.1715 · Difference in response rates: -7.28 · 95% CI -18.0 to 3.5The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) · Odds ratio (or): 0.80 · 95% CI 0.52 to 1.22
SecondaryStage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL

Overall Response comprised of CR, CRu, or PR . A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by \>75% in SPD. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper.

Time frame:
Stage I and II: Baseline up to 57 days after last maintenance dose (last maintenance dose: maintenance Cy12/Study Cy20 [30 months]) (up to data cutoff of 31 Oct 2017 [up to 6 years]) (1 Cy=8 weeks)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment Assessed Using International Working Group Response Criteria for NHL78.1 (71.3 to 83.9)77.9 (71.0 to 83.9)
Statistical analysis
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) · Chi-squared · p = 0.9671 · Difference in response rates: -0.18 · 95% CI -9.2 to 8.8The 95% CI for the difference in response rates was estimated using the Hauck-Anderson method.
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) · Odds ratio (or): 0.99 · 95% CI 0.60 to 1.64
SecondaryStage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death

Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

Time frame:
Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse or Death34.631.7
SecondaryStage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHL

PFS was defined as the time from randomization to disease progression/relapse or death due to any cause. If the specified event (disease progression/relapse, death) did not occur, PFS was censored at the last tumor assessment date showing no disease progression, either during treatment or follow-up. Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. PFS analysis was performed using Kaplan - Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

Time frame:
Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Reported as:
Median · days
Stage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHL
daysStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Progression-Free Survival (PFS) Assessed Using International Working Group Response Criteria for NHLNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) · Wald test · p = 0.5526 · Hazard ratio (hr): 0.90 · 95% CI 0.64 to 1.26
SecondaryStage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL

Disease progression: ≥50% increase from nadir in the SPD of any previously identified abnormal node or appearance of any new lesion during or at the end of therapy or ≥50% increase in the greatest diameter of any previously identified node \>1 cm in its short axis or in the SPD of more than one node. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

Time frame:
Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Percentage of Participants With Disease Progression/Relapse, New Anti-Lymphoma Treatment or Death Assessed Using International Working Group Response Criteria for NHL36.135.1
SecondaryStage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL

Event-free survival was defined as the time from randomization to disease progression/relapse, death or initiation of new NHL therapy. If the specified event (progression/relapse, death or new anti-lymphoma treatment) did not occur, event-free survival was censored at the last tumor assessment date either during treatment or follow up. Event-free survival analysis was performed using Kaplan-Meier curves. Baseline, D1 of all cycles (Cy 1-20) (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), at early withdrawal, at follow-up, every 12 weeks for 96 weeks or until documented disease progression/relapse or death (up to a median of 27 months; up to data cutoff of 31 Oct 2017 \[up to 6 years\])

Time frame:
Baseline up to disease progression or death up to data cutoff of 31 Oct 2017 (up to 6 years) (See detailed timeframe in Outcome Measure description)
Reported as:
Median · days
Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHL
daysStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I and II (Pooled): Event-Free Survival Assessed Using International Working Group Response Criteria for NHLNA (2126 to NA)NA (NA to NA)
Statistical analysis
  • Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) · Wald test · p = 0.9115 · Hazard ratio (hr): 0.98 · 95% CI 0.71 to 1.36
SecondaryPercentage of Participants Who Died
Time frame:
Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Percentage of Participants Who Died12.78.8
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Participants without event were censored at the time of last follow-up information for survival, ie, at the last time known to be alive.

Time frame:
Baseline up to death (up to data cutoff of 31 Oct 2017 [up to 6 years])
Reported as:
Median · days
Overall Survival (OS)
daysStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryStage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab

AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. Predose (within 2 hr) and 24 hrs postdose on Cy 7 (D1,3,7,15), predose (0 hr) on Cy 8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy 7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])

Time frame:
Stage I (Induction): Predose (within 2 hour [hr]) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)
Reported as:
Geometric mean · mcg*day/mL
Stage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab
mcg*day/mLStage I: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I: Observed Area Under the Serum Concentration-Time Curve (AUC) of Rituximab2734.21 ± 32.513778.93 ± 37.59
Statistical analysis
  • Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) · Geometric mean ratio: 1.38 · 90% CI 1.24 to 1.53
SecondaryStage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab

Predose (within 2 hr) and 24 hrs postdose on Cy7 (D1,3,7,15), predose (0 hr) on Cy8 D1 (1 Cy=3 weeks); additionally within 15 minutes after end of infusion (infusion duration=30 minutes) on Cy7 D1 for rituximab IV (up to data cutoff of 11 Apr 2012 \[up to 26 months\])

Time frame:
Stage I (Induction): Predose (within 2hr) up to data cutoff of 11 Apr 2012 [up to 26 months]) (See detailed timeframe in Outcome Measure description)
Reported as:
Geometric mean · mcg/mL
Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab
mcg/mLStage I: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I: Rituximab SC + Chemotherapy (CHOP/CVP)
Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab250.63 ± 19.66236.82 ± 31.45
Statistical analysis
  • Stage I: Rituximab IV + Chemotherapy (CHOP/CVP) vs Stage I: Rituximab SC + Chemotherapy (CHOP/CVP) · Geometric mean ratio: 0.941 · 95% CI 0.872 to 1.015
SecondaryStage I and II (Pooled): Ctrough of Rituximab at Each Induction Treatment Cycle

Stage I and II (Induction): Rituximab IV: Predose (within 2 hr) on D1 of Cy1-8 (1 Cy=3 weeks \& 4 weeks for Cy8); Rituximab SC: Predose (within 2 hr) on D1 of Cy1 \& Cy3-8 (1 Cy=3 weeks and 4 weeks for Cy8), predose (within 2 hr) on D0 of Cy2 (up to data cutoff of 31 Oct 2013 \[up to 32 months\])

Time frame:
Stage I and II (Pooled): Predose (within 2hr) up to data cutoff of 31 Oct 2013 [up to 32 months]) (See detailed timeframe in Outcome Measure description)
Reported as:
Geometric mean · mcg/mL
Stage I and II (Pooled): Ctrough of Rituximab at Each Induction Treatment Cycle
mcg/mLStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Cycle 1 (n = 198, 193)14.00 ± 157.5312.88 ± 189.70
Cycle 2 (n = 197, 190)30.13 ± 145.3640.00 ± 124.50
Cycle 3 (n = 192, 190)45.25 ± 110.3563.83 ± 101.83
Cycle 4 (n = 186, 185)54.06 ± 108.9081.71 ± 92.28
Cycle 5 (n = 185, 185)64.68 ± 89.9098.00 ± 71.91
Cycle 6 (n = 187, 180)71.02 ± 87.60109.56 ± 58.74
Cycle 7 (n = 183, 172)78.31 ± 77.76120.75 ± 55.60
Cycle 8 (n = 52, 54)77.60 ± 70.53131.48 ± 50.20
SecondaryStage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle

Stage I and II (maintenance): D29 of Cy8 (induction; 1 Cy=4 weeks), predose (within 2 hr) on D1 of Cy9 to 19 (maintenance Cy1 to 12 \[1 Cy=8 weeks\]; up to data cutoff of 11 Jan 2016 \[up to 6 years\])

Time frame:
Stage I and II (maintenance): Predose (within 2hr) up to data cutoff of 11 Jan 2016 [up to 6 years]) (See detailed timeframe in Outcome Measure description)
Reported as:
Geometric mean · mcg/mL
Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle
mcg/mLStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Cycle 8 (n = 174, 170)37.69 ± 94.3061.31 ± 65.52
Cycle 9 (n = 171, 168)30.35 ± 75.0349.47 ± 81.23
Cycle 10 (n = 164, 160)28.44 ± 84.6447.27 ± 73.03
Cycle 11 (n = 164, 157)28.77 ± 65.2846.70 ± 66.80
Cycle 12 (n = 160, 150)28.80 ± 56.9744.72 ± 68.74
Cycle 13 (n = 157, 150)28.84 ± 54.0444.32 ± 67.67
Cycle 14 (n = 153, 147)28.09 ± 55.6143.32 ± 67.97
Cycle 15 (n = 148, 143)28.19 ± 52.6944.11 ± 67.92
Cycle 16 (n = 150, 145)28.05 ± 57.1942.96 ± 64.32
Cycle 17 (n = 149, 143)28.24 ± 57.5142.82 ± 65.67
Cycle 18 (n = 143, 132)28.59 ± 62.0644.79 ± 68.56
Cycle 19 (n = 138, 131)27.75 ± 78.2643.69 ± 69.02
SecondaryStage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration
Time frame:
12 weeks, 24 weeks, and 36 weeks after the last rituximab administration (up to data cutoff of 11 Jan 2016 [up to 6 years])
Reported as:
Median · mcg/mL
Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration
mcg/mLStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Week 12: Follow-up Visit 1 (n = 117, 118)15.60 (0.70 to 80.40)22.35 (0.65 to 107.00)
Week 24: Follow-up Visit 2 (n = 88, 96)2.89 (0.58 to 17.40)5.19 (0.69 to 62.10)
Week 36: Follow-up Visit 3 (n = 38, 53)1.08 (0.52 to 51.40)2.02 (0.53 to 33.90)
SecondaryPercentage of Participants With B-Cell Depletion by Cycle for Induction Phase

Depletion is defined as a cluster of differentiation (CD) 19 value \<80 cells per cubic millimeter (cells/mm\^3).

Time frame:
Stage I and II (induction): for rituximab IV - D1 of Cy 1 to 8 (1 Cy=3 weeks); for rituximab SC - D1 of Cy 1 and Cy 3 to 8, D0 of Cy 2
Reported as:
Number · percentage of participants
Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Cycle 1 Day 1 - Baseline (n=188, 168)51.654.8
Cycle 2 Day 0 (n=183, 180)95.195.0
Cycle 3 Day 1 (n=175, 175)99.499.4
Cycle 4 Day 1 (n=178, 180)99.4100.0
Cycle 5 Day 1 (n=179, 176)100.0100.0
Cycle 6 Day 1 (n=173, 175)100.0100.0
Cycle 7 Day 1 (n=178, 173)100.0100.0
Cycle 8 Day 1 (n=175, 174)100.0100.0
SecondaryPercentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase

Depletion is defined as a CD19 value \<80 cells/mm\^3.

Time frame:
Stage I and II (maintenance): D1 of Cy 9 to 20 (1 Cy=8 weeks) (up to data cutoff of 11 Jan 2016 [up to 6 years])
Reported as:
Number · percentage of participants
Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Cycle 9 Day 1 (n=170, 161)99.4100.0
Cycle 10 Day 1 (n=165, 164)99.4100.0
Cycle 11 Day 1 (n=158, 158)99.4100.0
Cycle 12 Day 1 (n=151, 146)100.0100.0
Cycle 13 Day 1 (n=149, 143)100.0100.0
Cycle 14 Day 1 (n=152, 143)100.0100.0
Cycle 15 Day 1 (n=149, 140)100.0100.0
Cycle 16 Day 1 (n=142, 141)100.0100.0
Cycle 17 Day 1 (n=145, 142)100.0100.0
Cycle 18 Day 1 (n=141, 140)100.0100.0
Cycle 19 Day 1 (n=140, 138)100.0100.0
Cycle 20 Day 1 (n=139, 134)100.0100.0
SecondaryStage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs) to Rituximab

Levels of HACA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])

Time frame:
Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs) to Rituximab
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Baseline (n=208, 191)5.82.6
Post-Baseline (n=206, 197)1.52.0
SecondaryStage I and II (Pooled): Percentage of Participants Positive for Human Anti-Human Antibodies (HAHAs) to Rituximab

Levels of HAHA in serum were detected at Day 1 of each cycle up to Cycle 8 and at follow-up visit. Stage I and II: Baseline: pre-dose (72 hours prior) D1 of Cy1, Cy 3-20, D0 of Cy2 (1 Cy=3 weeks for Cy1-8 \& 8 weeks for Cy9-20), post-baseline: every 12 weeks after last rituximab administration until 96 weeks (a median of 27 months; up to data cutoff of 11 Jan 2016 \[up to 6 years\])

Time frame:
Stage I and II: Baseline, post-baseline (See detailed timeframe in Outcome Measure description)
Reported as:
Number · percentage of participants
Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Human Antibodies (HAHAs) to Rituximab
percentage of participantsStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Baseline (n=68, 188)10.311.2
Post-Baseline (n=66, 197)7.613.2
SecondaryStage I and II (Pooled): Percentage of Responses Showing Time Saved of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20

All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (\<) 1 hr, at least 1 hr but \<2 hrs, at least 2 hrs but \<3 hrs, at least 3 hrs but \<4 hrs, \>/=4 hrs. Staff were asked not to consider the time needed for the first IV administration. Analysis was done in all participants to show a comparison on the time saved by staffs when administered via SC and IV.

Time frame:
After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)
Reported as:
Number · percentage of responses
Stage I and II (Pooled): Percentage of Responses Showing Time Saved of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20
percentage of responsesAll Participants
After Cy8: <1 hour (n=166)11
After Cy8: ≥1 to <2 hours (n=166)20
After Cy8: ≥2 to <3 hours (n=166)35
After Cy8: ≥3 to <4 hours (n=166)18
After Cy8: ≥4 hours (n=166)16
After Cy15: <1 hour (n=130)13
After Cy15: ≥1 to <2 hours (n=130)17
After Cy15: ≥2 to <3 hours (n=126)34
After Cy15: ≥3 to <4 hours (n=130)14
After Cy15: ≥4 hours (n=130)22
After Cy20: <1 hour (n=126)14
After Cy20: ≥1 to <2 hours (n=126)32
After Cy20: ≥2 to <3 hours (n=126)21
After Cy20: ≥3 to <4 hours (n=126)13
After Cy20: ≥4 hours (n=126)19
SecondaryPercentage of Responses Who Showed Rituximab SC Formulation Convenient as Compared to Rituximab IV Formulation as Assessed by Physician/Nurse Opinion

All investigator physicians and nurses involved in this study were asked to complete question i.e. "Which formulation of rituximab (SC or IV) do you think is more convenient?" based on their experience with the rituximab SC and IV formulations across all participants and presented as rituximab SC is much more convenient; rituximab SC is a little more convenient; both formulations are equally convenient; rituximab IV is a little more convenient; and rituximab IV is much more convenient.

Time frame:
After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)
Reported as:
Number · percentage of responses
Percentage of Responses Who Showed Rituximab SC Formulation Convenient as Compared to Rituximab IV Formulation as Assessed by Physician/Nurse Opinion
percentage of responsesAll Participants
Cy8: Rituximab SC much more convenient (n=166)81
Cy8: Rituximab SC little more convenient (n=166)13
Cy8: Both formulations equally convenient (n=166)2
Cy8: Rituximab IV little more convenient (n=166)4
Cy8: Rituximab IV much more convenient (n=166)0
Cy15: Rituximab SC much more convenient (n=130)88
Cy15: Rituximab SC little more convenient (n=130)7
Cy15: Both formulations equally convenient (n=130)5
Cy15: Rituximab IV little more convenient (n=130)0
Cy15: Rituximab IV much more convenient (n=130)0
Cy20: Rituximab SC much more convenient (n=126)88
Cy20: Rituximab SC little more convenient (n=126)9
Cy20: Both formulations equally convenient (n=126)2
Cy20: Rituximab IV little more convenient (n=126)1
Cy20: Rituximab IV much more convenient (n=126)0

Adverse events

Collected over Baseline up to data cutoff date of 31 Oct 2017 (up to 6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)—76/210 (36.2%)187/210 (89%)
Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)—74/197 (37.6%)186/197 (94.4%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
Febrile neutropeniaBlood and lymphatic system disorders10/21012/197
PneumoniaInfections and infestations7/21011/197
NeutropeniaBlood and lymphatic system disorders4/2106/197
PyrexiaGeneral disorders5/2106/197
Neutropenic sepsisInfections and infestations4/2101/197
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/2101/197
SepsisInfections and infestations1/2103/197
ConstipationGastrointestinal disorders3/2100/197
DyspnoeaRespiratory, thoracic and mediastinal disorders3/2102/197
CystitisInfections and infestations1/2102/197
Most frequent other events
Showing 10 of 50
Most frequent other events
EventStage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)
NauseaGastrointestinal disorders47/21065/197
NeutropeniaBlood and lymphatic system disorders57/21065/197
ConstipationGastrointestinal disorders55/21050/197
CoughRespiratory, thoracic and mediastinal disorders32/21049/197
FatigueGeneral disorders38/21042/197
AstheniaGeneral disorders27/21035/197
DiarrhoeaGastrointestinal disorders35/21034/197
AnaemiaBlood and lymphatic system disorders26/21030/197
ParaesthesiaNervous system disorders27/21030/197
Upper respiratory tract infectionInfections and infestations26/21030/197

Baseline characteristics

Intent-to-Treat (ITT) Population included all participants who were randomized into study irrespective whether they received study drug or not.

Age, Continuous
Age, Continuous(years)Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)Total
Mean56.9 ± 12.6956.1 ± 12.6656.5 ± 12.67
Sex: Female, Male
Sex: Female, Male(Participants)Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)Total
Female99120219
Male10685191
08

Study locations

152 sites
  • Gosford Hospital; Cancer Care Services
    Gosford, New South Wales 2250, Australia
  • Wollongong Hospital; Cancer Services
    Wollongong, New South Wales 2500, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Gold Coast Hospital; Haematology Department
    Southport, Queensland 4215, Australia
  • Queen Elizabeth Hospital; Haematology
    Woodville South, South Australia 5011, Australia
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • Sint Augustinus Wilrijk
    Wilrijk, 2610, Belgium
  • University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept
    Banja Luka, 88000, Bosnia and Herzegovina
  • University Clinical Center Sarajevo, Clinic for Hematology
    Sarajevo, 71000, Bosnia and Herzegovina
  • University Clinical Centre Tuzla, Clinic for Oncology, Hematology and Radiotherapy
    Tuzla, 75000, Bosnia and Herzegovina
  • Nucleo de Hematologia e Transplante de Medula Ossea de Minas Gerais
    Belo Horizonte, MG 30140-001, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-003, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Santa Casa de Misericordia de Sao Paulo; Hematologia e Hemoterapia
    Sao Paulo, SP 01221-020, Brazil
  • Hospital das Clinicas - FMUSP
    Sao Paulo, SP 05403-000, Brazil
  • UMHAT Dr Georgi Stranski; Hematology
    Pleven, 5800, Bulgaria
  • Umhat S. George; Hematology
    Plovdiv, 4002, Bulgaria
  • Specialised Hospital For Treatment Of Hematological Diseases; Hematology
    Sofia, 1756, Bulgaria
  • Mhat Sveta Marina; Dept. of Haematology
    Varna, 9010, Bulgaria
  • Queen Elizabeth II Health Sciences Centre; Oncology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Cite de La Sante de Laval; Hemato-Oncologie
    Laval, Quebec H7M 3L9, Canada
  • Centre de sante et de services sociaux Rimouski Neigette
    Rimouski, Quebec G5L 5T1, Canada
  • Centre Hospitalier Universitaire de Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
  • Centre hospitalier regional de Trois-Rivieres
    Trois-Rivieres, Quebec G8Z 3R9, Canada
  • CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie
    Quebec, G1J 1Z4, Canada
  • Fundacion Cardioinfantil
    Bogota, Colombia
  • Centro Medico Imbanaco
    Cali, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin-Antioquia, Colombia
  • Oncólogos de Occidente
    Pereira, 600004, Colombia
  • UHC Rijeka
    Rijeka, 51000, Croatia
  • University Hospital Center Zagreb; Haematology Department
    Zagreb, 10000, Croatia
  • Herlev Uni Hospital; Hæmatologisk Afdeling L 121
    Herlev, 2730, Denmark
  • Rigshospitalet; Hæmatologisk Klinik
    København Ø, 2100, Denmark
  • Odense Universitetshospital; Hæmatologisk Afdeling
    Odense C, 5000, Denmark
  • Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium
    Roskilde, 4000, Denmark
  • Vejle Hospital; Dept of Medicine, Division of Hematology
    Vejle, 7100, Denmark
  • Aarhus Universitetshospital, Hæmatologisk Afdeling R
    Århus, 8000, Denmark
  • Helsinki University Central Hospital; Dept of Oncology
    Helsinki, 00029, Finland
  • Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
    Bordeaux, 33077, France
  • Hopital Henri Mondor; Hematologie Clinique
    Creteil, 94010, France
  • Chu Site Du Bocage;Hematologie Clinique
    Dijon, 21079, France
  • Clinique Victor Hugo; Chimiotherapie
    Le Mans, 72015, France
  • Institut J Paolii Calmettes; Onco Hematologie 1
    Marseille, 13273, France
  • Hopital Saint Eloi; Hematologie Oncologie Medicale
    Montpellier, 34295, France
  • Hopital Hotel Dieu Et Hme;Hopital De Jour
    Nantes, 44093, France
  • Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)
    Paris, 75475, France
  • Hopital De Haut Leveque; Hematologie Clinique
    Pessac, 33604, France
  • Ch Lyon Sud; Hemato Secteur Jules Courmont
    Pierre Benite, 69495, France
  • Hopital De La Miletrie; Hematologie Et Oncologie Medicale
    Poitiers, 86021, France
  • Hopital Bretonneau; Hematologie Therapie Cellulaire
    Tours, 37044, France
  • M.Zodelava's Hematology Center
    Tbilisi, 0112, Georgia
  • Mediclub
    Tbilisi, 0160, Georgia
  • Institute of Hematology and Transfusiology
    Tbilisi, 0177, Georgia
  • Chemotherapy and Immunotherapy Clinic Medulla
    Tbilisi, 0186, Georgia
  • Onkologische Schwerpunktpraxis Kurfürstendamm
    Berlin, 10707, Germany
  • Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
    Darmstadt, 64283, Germany
  • Gemeinschaftspraxis Dr. med. J. Mohm und Dr. med. G. Prange-Krex; Fachaerzte fuer Innere Medizin
    Dresden, 01307, Germany
  • PIOH PD Dr. R. Schnell - Dr. H. Schulz - Dr. M. Hellmann
    Frechen, 50226, Germany
  • Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik I
    Giessen, 35392, Germany
  • Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik
    Greifswald, 17475, Germany
  • Internistisch-Onkologische Gemeinschaftspraxis; Dres. Rohrberg, Hurtz, Schma usw.
    Halle, 06110, Germany
  • Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie
    Hannover, 30625, Germany
  • St. Vincentius Kliniken Ag; Medizinische Klinik Abt. 2
    Karlsruhe, 76137, Germany
  • UKSH Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie
    Kiel, 24105, Germany
  • Gemeinschaftspraxis PD Dr. med. Marcel Reiser und Dr. med. Ildiko Kátay
    Koeln, 50674, Germany
  • Onkologische Gemeinschaftspraxis
    Magdeburg, 39104, Germany
  • Gemeinschaftspraxis Fr. Dr. med. Balser & Hr. Dr. med. Weidenbach
    Marburg, 35037, Germany
  • Medizinisches Versorgungszentrum MOP
    München, 80335, Germany
  • Praxis Dr.med. Jens Uhlig
    Naunhof, 04683, Germany
  • Praxis Dr. Clemens Müller-Naendrup (Onkologische Schwerpunktpraxis im MVZ 2 GmbH)
    Olpe, 57462, Germany
  • Prosper-Hospital, Medizinische Klinik I
    Recklinghausen, 45659, Germany
  • Praxis Dr. Fenchel
    Saalfeld, 07318, Germany
  • Caritas Kilinik St. Theresia; Abt. Innere Medizin
    Saarbruecken, 66113, Germany
  • Praxis für Hämatologie & Onkologie
    Saarbruecken, 66113, Germany
  • Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine
    Athens, 115 27, Greece
  • Attiko Hospital; Haematology Clinic
    Athens, 124 62, Greece
  • Azienda Ospedaliera Ospedale S.Carlo; Ematologia
    Potenza, Basilicata 85100, Italy
  • A.O. Universitaria Federico II Di Napoli; Oncologia Ed Endocrinologia Clinica
    Napoli, Campania 80131, Italy
  • AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Ospedale S. Eugenio; Divisione Di Ematologia
    Roma, Lazio 00144, Italy
  • Uni Degli Studi Di Genova; 1A Divisione Di Ematologia
    Genova, Liguria 16132, Italy
  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
    Brescia, Lombardia 25123, Italy
  • Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia
    Milano, Lombardia 20141, Italy
  • IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo
    San Giovanni Rotondo, Puglia 71013, Italy
  • Ospedale Ca Foncello; Ematologia
    Treviso, Veneto 31100, Italy
  • Ospedale Di Vicenza; Nefrologia, Ematologia
    Vicenza, Veneto 36100, Italy
  • University Clinic for Hematology; HSCT Department
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • University Clinic of Hematology Skopje, Hospital Care Department
    Skopje, 1000, Macedonia, The Former Yugoslav Republic of
  • University Malaya Medical Center; Hematology Unit of Department of Internal Medicine
    Kuala Lumpur, FED. Territory OF Kuala Lumpur 59100, Malaysia
  • Ampang Hospital; Department of Haematology
    Ampang, 68000, Malaysia
  • Sarawak General Hospital; Department of Radiotherapy, Oncology and Palliative care
    Sarawak, 93586, Malaysia
  • Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre
    Chihuahua, 31000, Mexico
  • Hospital General De Culiacan; Servicio De Hematologia
    Culiacan, 80230, Mexico
  • Hospital Universitario Dr. Jose E. Gonzalez; Haematology
    Monterrey, 64460, Mexico
  • Centro de Estudios Clinicos de Queretaro (CECLIQ)
    Queretaro, 76000, Mexico
  • Canterbury Health Laboratories; Haematology
    Christchurch, 8011, New Zealand
  • Palmerston North Hospital; Regional Cancer Treatment Service
    Palmerston North, 4442, New Zealand
  • Instituto;Oncologico Miraflores
    Lima, 18, Peru
  • Oncosalud Sac; Oncología
    Lima, 41, Peru

Showing the first 100 of 152 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, Boehnke A, Berge C, Genevray M, Zharkov A, Dixon M, Brewster M, Barrett M, MacDonald D. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Jun;4(6):e272-e282. doi: 10.1016/S2352-3026(17)30078-9. Epub 2017 May 2. PubMed 28476440 ↗
  • Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Celigny P, Barrett M, Berge C, Bittner B, Boehnke A, McIntyre C, Macdonald D. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014 Mar;15(3):343-52. doi: 10.1016/S1470-2045(14)70005-1. Epub 2014 Feb 10. PubMed 24521993 ↗
  • Mao CP, Brovarney MR, Dabbagh K, Birnbock HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One. 2013 Nov 12;8(11):e80533. doi: 10.1371/journal.pone.0080533. eCollection 2013. PubMed 24265828 ↗
  • Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013 Sep 17;109(6):1556-61. doi: 10.1038/bjc.2013.371. Epub 2013 Sep 3. PubMed 24002601 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Jun 2012, 15 months.

Results were first posted in Aug 2015, 3 years 1 month after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 15 months is below that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2010
First posted
Sep 14, 2010
StartActual
Feb 15, 2011
Primary completionActual
Jun 12, 2012
CompletionActual
Oct 31, 2017
Results first posted
Aug 5, 2015
Last update
Nov 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01200758
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 14, 2010
Start date
Feb 15, 2011
Primary completion
Jun 12, 2012
Completion
Oct 31, 2017
Results posted
Aug 5, 2015
Last update
Nov 27, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion